Marengo Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $80M

  • Investors
  • 1

Marengo Therapeutics General Information

Description

Developer of immunotherapy products designed for the treatment of cancer and autoimmune diseases. The company utilizes a proprietary library of antibodies targeting germline-encoded variable Vβ regions of the T-cell receptor to selectively modulate immune cell subsets, enabling oncology and autoimmune companies to combine selective T-cell activation and expansion with tumor-directed engagement to enhance antitumor potency while limiting indiscriminate immune activation.

Contact Information

Formerly Known As
Elstar Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 840 Memorial Drive
  • 4th Floor
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 840 Memorial Drive
  • 4th Floor
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Marengo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) 08-Nov-2021 $80M Completed Startup
1. Early Stage VC (Series A) 03-Jan-2018 Completed Startup
To view Marengo Therapeutics’s complete valuation and funding history, request access »

Marengo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Marengo Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Marengo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunotherapy products designed for the treatment of cancer and autoimmune diseases. The company utilizes a
Drug Discovery
Cambridge, MA
43 As of 2026

Lebanon, NH
 

Indianapolis, IN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Marengo Therapeutics Competitors (103)

One of Marengo Therapeutics’s 103 competitors is Adimab, a Venture Capital-Backed company based in Lebanon, NH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adimab Venture Capital-Backed Lebanon, NH
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
Ayala Pharmaceuticals Corporation Wilmington, DE
Adicet Bio Formerly VC-backed Boston, MA
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
You’re viewing 5 of 103 competitors. Get the full list »

Marengo Therapeutics Patents

Marengo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112599-A2 Combination therapy of a parp inhibitor and a multifunctional molecule binding to tcr Pending 25-Nov-2024
WO-2026112599-A3 Combination therapy of a parp inhibitor and a multifunctional molecule binding to tcr Pending 25-Nov-2024
WO-2026096770-A2 Multispecific molecules binding to tcr and uses thereof Pending 30-Oct-2024
WO-2026096770-A3 Multispecific molecules binding to tcr and uses thereof Pending 30-Oct-2024
WO-2026072811-A2 Tcr targeting molecules and uses thereof Pending 25-Sep-2024 C07K16/2809
To view Marengo Therapeutics’s complete patent history, request access »

Marengo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Marengo Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apple Tree Partners (ATP) Venture Capital Minority
To view Marengo Therapeutics’s complete investors history, request access »

Marengo Therapeutics FAQs

  • When was Marengo Therapeutics founded?

    Marengo Therapeutics was founded in 2015.

  • Where is Marengo Therapeutics headquartered?

    Marengo Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Marengo Therapeutics?

    Marengo Therapeutics has 43 total employees.

  • What industry is Marengo Therapeutics in?

    Marengo Therapeutics’s primary industry is Drug Discovery.

  • Is Marengo Therapeutics a private or public company?

    Marengo Therapeutics is a Private company.

  • What is Marengo Therapeutics’s current revenue?

    The current revenue for Marengo Therapeutics is .

  • How much funding has Marengo Therapeutics raised over time?

    Marengo Therapeutics has raised $119M.

  • Who are Marengo Therapeutics’s investors?

    Apple Tree Partners (ATP) has invested in Marengo Therapeutics.

  • Who are Marengo Therapeutics’s competitors?

    Adimab, Apexian Pharmaceuticals, Ayala Pharmaceuticals, Adicet Bio, and Light Chain Bioscience are some of the 103 competitors of Marengo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process